Pharmacyclics Appoints Chief Commercial Officer
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has appointed Shawn Cline Tomasello as its Chief Commercial Officer. Ms. Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4 billion in revenue. Prior to joining Celgene, Ms. Cline Tomasello was the National Director of Hematology for Rituxan® at Genentech, where she was responsible for over $1.7 billion in revenue.
"We are delighted to welcome Shawn in this important position," said Bob Duggan, Chairman & CEO, Pharmacyclics. "During her career, she has led commercial teams for two of the most successful global hematology products in the industry. Her exceptional and proven leadership skills and depth of experience within the hematology-oncology space will be tremendously valuable to the ongoing success and growth of IMBRUVICA® and to our company."
Ms. Cline Tomasello had been with Celgene since 2005, where she was responsible for all aspects of commercial sales and marketing for six brands encompassing 11 indications. In addition, she was instrumental in strategic decision making regarding global expansion and M&A evaluations which led to the acquisition and integration of Pharmion Corporation, Gloucester Pharmaceuticals, Inc. and Abraxis Biosciences, Inc.
Previously, Ms. Cline Tomasello was at Genentech for 16 years, where she was the National Director for Rituxan responsible for all in-line and new indications for the hematology commercial organization. At that time, Rituxan represented the majority of the company's corporate revenue. In addition, she held positions at Pfizer Laboratories, Miles Pharmaceuticals and Proctor & Gamble earlier in her career.
Ms. Cline Tomasello received her B.S. in marketing from the University of Cincinnati and her M.B.A. from Murray State University, KY.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.